ライフサイエンスコーパス: portal vein

1 S allowed blood samples to be taken from the portal vein.

2 V) joining with the splenic vein to form the portal vein.

3 rointestinal (GI) tract to the liver via the portal vein.

4 r above, below, and at the level of the main portal vein.

5 supply comes from the intestine through the portal vein.

6 ated CpG containing DNA to the liver via the portal vein.

7 between hepatic artery or its branch and the portal vein.

8 ity of noncancerous liver is supplied by the portal vein.

9 y artery and between TRPC5 and TRPC7 only in portal vein.

10 rabbit coronary and mesenteric arteries and portal vein.

11 y artery and anti-TRPC7 blocked SOCs only in portal vein.

12 nary artery similar to mesenteric artery and portal vein.

13 sic contractile behaviour similar to that of portal vein.

14 0.001) and D3 cortisone (P < 0.01) into the portal vein.

15 that occurs when islets are infused into the portal vein.

16 ozotocin-induced diabetic mice (H-2) via the portal vein.

17 f gas in the mesenteric veins but not in the portal vein.

18 tion-versus-time curves in the liver and the portal vein.

19 the mixed tracer input to the liver via the portal vein.

20 oppler ultrasonography was used to check the portal vein.

21 se-contrast images were also acquired in the portal vein.

22 tively), pancreas (151.2 HU vs 67.0 HU), and portal vein (189.7 HU vs 87.3 HU), along with a greater

23 d at least one injury, most commonly a short portal vein (21.5%).

24 Results Occlusion was identified in 39.7% of portal veins (29 of 73), 15.0% of hepatic veins (six of

25 the CBD decreased to 62% after clamping the portal vein, 51% after clamping the hepatic artery, and

26 eedle was advanced transhepatically into the portal vein and as many as four 7.5-mL aliquots of blood

27 th the initiation of E23 splicing as the rat portal vein and avian gizzard implement the fast program

28 Portal vein and bile duct area index were significantly

29 ion and mesenteric artery high/low flow, the portal vein and first order mesenteric artery dynamicall

30 In the second case, the preduodenal portal vein and hemiazygos continuation with interruptio

31 IP was induced by clamping the portal vein and hepatic artery for 9 min.

32 ernative porto-caval shunt between the right portal vein and inferior vena cava detected on postnatal

33 rect chylomicron deposition via misconnected portal vein and intestinal lymphatic systems.

34 iponectin concentrations were similar in the portal vein and radial artery in obese subjects.

35 at 10 microm increased TRPC6/C7 activity in portal vein and reduced association between TRPC7 and PI

36 n fast smooth muscle tissues such as the rat portal vein and small mesenteric artery, in which E23 is

37 However, the contribution of the portal vein and the gastroduodenal artery to the bile du

38 ever, the liver receives blood from both the portal vein and the hepatic artery, with the peak of the

39 lanted with 350 syngeneic islets through the portal vein and treated once-daily with either rapamycin

40 peared ischemic with a flattened right lobar portal vein and vena cava without any visible active ble

41 ugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were a

42 , 17 (17.3%) had cavernous transformation of portal vein, and 3 (3.1%) had post-transplant thrombosis

43 portal venous phase were obtained in liver, portal vein, and aorta for each group and were summed fo

44 This study emphasizes the importance of the portal vein, and disturbances in portal venous blood flo

45 In the present study, arterial, portal vein, and hepatic vein sampling catheters were su

46 Attenuation of aorta, main portal vein, and liver were measured.

47 vels were also determined from hepatic vein, portal vein, and systemic arterial blood in seven patien

48 d texture mapping of tumors, hepatic artery, portal vein, and the hepatic veins was developed.

49 of vagal nerve supply to the liver, hepatic portal vein, and the proximal duodenum provided by the c

50 from the gastrointestinal tract through the portal vein, and thereby is exposed continuously to diet

51 expressions were both decreased in Dicer KO portal veins, and inhibition of L-type channels in contr

52 resistant to vessel occlusion compared with portal veins, and only arterial patency within an ablati

53 Portal vein angioplasty/stenting is conventionally perfo

54 arge amounts of unmodified folic acid in the portal vein are probably attributable to an extremely li

55 A portal vein area index <0.08 had a lower chance of succe

56 Low portal vein area index and intraoperative portal blood i

57 the intestinal mucosa and transferred to the portal vein as the natural circulating plasma folate, 5-

58 ivers perfused with autologous blood via the portal vein at 60, 70, 80, 90, and 100 mL/min per 100 g

59 model perfused with autologous blood via the portal vein at five flow rates (60, 70, 80, 90, and 100

60 model perfused with autologous blood via the portal vein at three flow rates (60, 80, 100 mL/min per

61 (every 6 months) were performed to check the portal vein axis.

62 ially relatively sparse mesh surrounding the portal vein becomes five-fold denser through elongation,

63 sectable PBCs had a mean of 83.2 CTCs/7.5 mL portal vein blood (median, 62.0 CTCs/7.5 mL portal vein

64 There were no complications from portal vein blood acquisition.

65 We identified CTCs in all portal vein blood samples from patients with PBCs, but l

66 portal vein blood (median, 62.0 CTCs/7.5 mL portal vein blood).

67 BCs had a mean of 118.4 +/- 36.8 CTCs/7.5 mL portal vein blood, compared with a mean of 0.8 +/- 0.4 C

68 SOCs in coronary and mesenteric arteries and portal vein but anti-TRPC6 blocked SOCs only in coronary

69 TRPC7 antibodies blocked channel activity in portal vein but only anti-TRPC6 inhibited activity in me

70 C6 and TRPC7 proteins strongly associated in portal vein but only weakly associated in mesenteric art

71 s associated with islet infusion through the portal vein by reducing the amount of transplanted tissu

72 ere is a recent focus on embolization of the portal vein by transplanted islets as a major cause of e

73 develop early after LT, the occlusion of the portal vein can have catastrophic consequences to the gr

74 ein (SMV) and/or portal vein (hereafter, SMV/portal vein) contact (r = -0.38), and post-CRT superior

75 ta-HSD1 activity is insufficient to increase portal vein cortisol concentrations and hence to influen

76 a-HSD1 from adipose tissue and its effect on portal vein cortisol concentrations have not been quanti

77 In 3 patients, MAA deposits in the portal vein could accurately be attributed to tumor thro

78 Portal vein CTCs can be used for molecular characterizat

79 In a selected patient, portal vein CTCs were found to carry the same mutations

80 Ratios of arterial and portal vein D4 cortisol/cortisol(total) (0.06 +/- 0.01 v

81 f 21 patients with target tumors adjacent to portal veins developed mild to moderate cholestasis 2-6

82 latelet count was associated with increasing portal vein diameter, splenomegaly, increased serum immu

83 2.2 mm+/-0.59 vs 1.6 mm+/-0.40, P<.001), but portal vein diameters were not significantly different.

84 as measured at baseline, during clamping the portal vein, during clamping the hepatic artery, and dur

85 the clinical outcome of patients undergoing portal vein embolization (PVE) and autologous CD133 bone

86 her the future liver remnant will grow after portal vein embolization (PVE) in patients with colon ca

87 ient size of the future liver remnant (FLR), portal vein embolization (PVE) of the tumor-bearing live

88 Preoperative portal vein embolization has thus far been established a

89 Portal vein embolization improves the safety of liver re

90 Portal vein embolization is associated with increased TG

91 Portal vein embolization is used to increase future remn

92 Portal vein embolization may be indicated in selected pa

93 Portal vein embolization was performed in 28 patients di

94 pproaches along with the use of preoperative portal vein embolization, hepatic and caudate lobe resec

95 herapies are transcatheter therapies such as portal vein embolization, hepatic artery infusion chemot

96 phasizing the importance of measures such as portal vein embolization, hepatic pedicle clamping and p

97 r: strategy, stage of the procedure, access, portal vein embolization, if used, types of transection

98 d strategies for utilization of preoperative portal vein embolization, transjugular intrahepatic port

99 ce were elevated CA 19-9 (HR 1.8; P = 0.01), portal vein encasement (HR 3.3; P = 0.007), and residual

100 These changes seemed to result in enhanced portal vein endotoxin concentrations and fatty liver dis

101 sion Unlike monopolar RF ablation, change in portal vein flow rates does not have a statistically sig

102 rpose To investigate the effect of change in portal vein flow rates on the size and shape of ablation

103 s a reduction in hepatic artery flow volume, portal vein flow volume and total flow volume that was n

104 s used to examine portal vein peak velocity, portal vein flow volume, hepatic artery resistive index

105 pectrometry with (ii) direct sampling of the portal vein following an intravenous glucose/arginine ch

106 eratively, blood samples were taken from the portal vein for measurement of CTCs before and immediate

107 During somatostatin and basal portal vein glucagon infusion, insulin was infused porta

108 events mediating the pleiotropic actions of portal vein glucose (PoG) delivery on hepatic glucose di

109 ycemia plus either 4x basal insulin (INS) or portal vein glucose infusion (PoG) was measured.

110 synthesis during hyperinsulinemia or hepatic portal vein glucose infusion in vivo.

111 mic clamp was established in the presence of portal vein glucose infusion.

112 lycemic-hyperinsulinemic challenge including portal vein glucose infusion.

113 Specifically, it is unlikely that a hepatic portal vein glucose sensor signaling RYGB-induced increa

114 tially sensing glucose levels in the hepatic portal vein has recently been suggested in a mouse model

115 measured systemic and regional hemodynamics (portal vein, hepatic and right kidney artery ultrasound

116 measured systemic and regional hemodynamics (portal vein, hepatic and right kidney artery ultrasound

117 infusion with simultaneous sampling from the portal vein, hepatic vein, and an arterialized periphera

118 Complete occlusion of the portal veins, hepatic veins, and hepatic arteries within

119 nge in superior mesenteric vein (SMV) and/or portal vein (hereafter, SMV/portal vein) contact (r = -0

120 Portal vein hypertension (PVH) in liver cirrhosis compli

121 Portal vein IL-6 concentration correlated directly with

122 ferior mesenteric veins merged to become the portal vein in all but one case in which the inferior me

123 uity with the inferior mesenteric artery and portal vein in continuity with the inferior mesenteric v

124 Vector delivery via the portal vein in hemophilia A and B dogs was well tolerate

125 anted into mdr2(-/-) mice livers through the portal vein in the presence or absence of GTN.

126 ) were lower in the hepatic vein than in the portal vein, indicating production of both cortisol and

127 Portal vein infusion of 16:0/18:1-GPC induced PPARalpha-

128 were infused with somatostatin, followed by portal vein infusion of insulin and glucagon.

129 hepatic metastatic cancer was developed with portal vein infusion of luciferase-expressing melanoma B

130 d islets were transplanted into patients via portal vein infusion.

131 echnique, with immediate transplantation via portal vein infusion.

132 (residues 331-580) into permeabilized rabbit portal vein inhibited Ca2+ sensitized force and activati

133 lencing of the endogenous p63RhoGEF in mouse portal vein inhibits contractile force induced by endoth

134 livers exposed to the same three patterns of portal vein insulin delivery by use of sequential liver

135 Using a pancreatic clamp, hepatic portal vein insulin delivery was increased three- or eig

136 Thus small increments in portal vein insulin have major consequences on the liver

137 ere as follows: variant entrance of the main portal vein into the liver and atypically located superi

138 re (P = .022), tumor burden (P < .001), main portal vein invasion (P = .033), and arterioportal shunt

139 lobar, bilobar), tumor burden (</=50%, 50%), portal vein invasion (present, absent), and arterioporta

140 [69.4% sessions (n = 77)] or B; ascites and portal vein invasion was present in 18 (16.2%) and 15 (1

141 the setting of hepatocellular carcinoma with portal vein invasion, and for radiation segmentectomy.

142 ic structure, tumor burden greater than 50%, portal vein invasion, and shunting had confirmed associa

143 ifferent grades, with presence or absence of portal vein invasion, with presence or absence of cirrho

144 of beta-cells in islets transplanted via the portal vein is caused by excess insulin-stimulated lipog

145 ulsatile insulin secretion delivered via the portal vein is important for hepatic insulin action and,

146 The portal vein is inaccessible in humans, and methods of es

147 Phasic contractile activity in rat portal vein is more sensitive to the rate of change in l

148 Based on the premise that high portal vein levels of nutrients and incretins would stim

149 nce whether measured at the upper, lower, or portal vein levels within the right lobe of the liver.

150 , CCl(4)-induced ascitic cirrhosis and 2-day portal vein-ligated (PVL) animals.

151 Sham, portal vein-ligated (PVL), and 4-week biliary duct-ligat

152 We induced prehepatic PH by partial portal vein ligation (PPVL) in germ-free (GF) or mice co

153 ALPPS combines portal vein ligation (PVL) with liver transection (step

154 the first step, surgical exploration, right portal vein ligation (PVL), and in situ splitting (ISS)

155 ation after extended partial hepatectomy and portal vein ligation for multiple bilobar CRLM were appl

156 ation after extended partial hepatectomy and portal vein ligation for multiple bilobar CRLM were appl

157 djustment in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) occu

158 Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), a 2

159 tality after Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS), ava

160 r regeneration after partial hepatectomy and portal vein ligation, and increased the expression of ce

161 r regeneration after partial hepatectomy and portal vein ligation, and increased the expression of ce

162 d portal hypertension was induced by partial portal vein ligation.

163 ss-severe forms of portal hypertension after portal vein ligation.

164 Cl4 intoxication) and non-cirrhotic (partial portal vein ligation/PPVL) rats received either atorvast

165 n liver injury or KC activation, even though portal vein LPS levels were elevated.

166 creased intestinal permeability and elevated portal vein LPS levels, evidence of hepatocyte injury an

167 g the dual-input time-activity curve without portal vein measurements are being developed.

168 ere, we report that Jag1 inactivation in the portal vein mesenchyme (PVM), but not in the endothelium

169 eased in HCC tissue specimens, especially in portal vein metastasis or intrahepatic metastasis, compa

170 artery, superior mesenteric artery, and main portal vein (MPV).

171 cially on thrombotic total occlusion of main portal vein (MPV).

172 AG) on TRPC6-like channel activity in rabbit portal vein myocytes using single channel recording and

173 7 activity from inhibition by diC8-PIP(2) in portal vein myocytes, and this was not prevented by the

174 but inhibited SOCs in mesenteric artery and portal vein myocytes.

175 ed channel (SOC) in freshly dispersed rabbit portal vein myocytes.

176 ons for MesoRex bypass (MRB) in extrahepatic portal vein obstruction and the role of primary prophyla

177 Liver cirrhosis but also portal vein obstruction cause portal hypertension (PHT)

178 Therefore, children with extrahepatic portal vein obstruction should be offered MRB for primar

179 vast majority of children with extrahepatic portal vein obstruction will experience complications th

180 In portal vein obstruction, statins enhanced the canonical

181 Portal vein occlusion (PVO) was used in 44 patients.

182 Of these, 87 (34%) IU patients required portal vein occlusion after chemotherapy downstaging.

183 requiring 12 or more chemotherapy cycles and portal vein occlusion to achieve resectability, is assoc

184 Portal vein occlusion was only significantly correlated

185 y hepatocytes at concentrations found in the portal vein of animals (60-80 muM).

186 injection of CT26.CL25 cancer cells into the portal vein of BALB/c mice.

187 venous sac made from lumbar vein or into the portal vein of syngeneic rats.

188 vasion into the extra-hepatic portion of the portal vein or the development of distant metastases ren

189 cal abnormalities of islets infused into the portal veins or to drug toxicity.

190 immediately adjacent to major hepatic veins, portal veins, or both; thus, they were not considered su

191 e lower level, and was 0.047 +/- 0.10 at the portal vein (P = .02).

192 ncement for the aorta, the pancreas, and the portal vein; pancreas-to-tumor contrast-to-noise ratio (

193 Two radiologists evaluated portal vein patency and intrahepatic portal branches, th

194 While the difference in portal vein peak velocity in the hepatosteatosis and con

195 Doppler ultrasonography was used to examine portal vein peak velocity, portal vein flow volume, hepa

196 increased interleukin-17A (IL-17A) levels in portal vein plasma and small intestine.

197 creased clot formation rate, associated with portal vein platelet aggregates and reductions in protei

198 oad/pressure in a way that is different from portal vein, possibly because the pacemaker for generati

199 graft with concomitant focus on keeping the portal vein pressure below 20 mm Hg.

200 Portal vein pressure was measured; morphology of the hep

201 onse to glucose occurred in gastric- than in portal vein-projecting neurons, the latter having a high

202 ifferentially distributed among gastric- and portal vein-projecting nodose neurons.

203 nderwent 2D phase-contrast MR imaging of the portal vein (PV) and infrahepatic and suprahepatic infer

204 arginal islet dose (150 islets), or into the portal vein (PV) at a full dose (500 islets).

205 Portal vein (PV) complications after living donor liver

206 asound measurement of right (R) and left (L) portal vein (PV) diameters and Urata's standard liver vo

207 ated rats underwent afferent ablation of the portal vein (PV) or portal and superior mesenteric veins

208 Chronic, obliterative portal vein (PV) thrombosis (PVT) represents a relative

209 In case of portal vein (PV) thrombosis (PVT), renoportal anastomosi

210 or mesenteric vein (SMV), splenic vein (SV), portal vein (PV), and the TIPS.

211 t of PVT patients requiring nonphysiological portal vein reconstruction was associated with higher co

212 performed in 54% of cases, with arterial and portal vein resections in 15% and 32%, respectively.

213 covered extrinsic compression of hepatic and portal veins, resulting in functional Budd-Chiari syndro

214 For the 5 patients with complete portal vein revascularization who underwent lobar hepate

215 We detected CTCs in portal vein samples from all 18 patients (100%) vs perip

216 Because portal vein sampling is not feasible in humans, assumpti

217 Measurement of insulin levels in the portal vein showed a time window of absorption that was

218 in phasic smooth muscle tissues, such as the portal vein, small intestine, and small mesenteric arter

219 thrombosis (nonsignificant [NS]), and one of portal vein stenosis (NS).

220 Portal vein stenosis (PVS) or thrombosis (PVT) are uncom

221 Persistence of SMV/portal vein stenosis after CRT was not predictive of R1

222 area, total lumen area, and diameter of main portal vein, superior mesenteric vein, and splenic vein.

223 x 2 cm x 2.1 cm in size with abutment of the portal vein-superior mesenteric vein confluence for less

224 gh pancreaticoduodenectomy (PD) with en-bloc portal vein/superior mesenteric vein (PV/SMV) resection

225 at low metformin concentrations found in the portal vein suppress glucose production in hepatocytes t

226 and soluble factors circulating through the portal vein system by releasing tremendous amounts of di

227 entration was approximately 20% lower in the portal vein than in the radial artery in obese subjects

228 tration was approximately 50% greater in the portal vein than in the radial artery in obese subjects

229 Therefore in portal vein the conductance consists of TRPC6/C7 subunit

230 ast, the viscera releases cortisone into the portal vein, thereby providing substrate for intrahepati

231 bursts at ~5-min intervals into the hepatic portal vein, these pulses being attenuated early in the

232 discrimination between bland and neoplastic portal vein thrombi when the ratio of the ADC of the thr

233 were mainly rejected for comorbidity (19%), portal vein thrombosis (16%), previous surgery (9%), obe

234 ently in OPV than in cirrhosis: extrahepatic portal vein thrombosis (18 [43%] of 42 vs five [12%] of

235 s of the liver in children with extrahepatic portal vein thrombosis (EHPVT), with surgical outcome af

236 n associated with hepatic artery (n = 15) or portal vein thrombosis (n = 14).Mean surgical time was 1

237 pared with non-BCS liver recipients), one of portal vein thrombosis (nonsignificant [NS]), and one of

238 logy Group (ECOG), presence of cirrhosis and portal vein thrombosis (PVT) (none, branch, and main).

239 Portal vein thrombosis (PVT) and different cardiovascula

240 patients of liver cirrhosis associated with portal vein thrombosis (PVT) can be effectively treated

241 In cirrhosis, portal vein thrombosis (PVT) could be a cause or a conse

242 low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced c

243 Portal vein thrombosis (PVT) is common in patients with

244 Nonneoplastic portal vein thrombosis (PVT) is frequent in patients wit

245 ate and survival of hepatocellular carcinoma portal vein thrombosis (PVT) patients treated with (90)Y

246 Patients with Child-Pugh B disease who had portal vein thrombosis (PVT) survived 5.6 months (95% co

247 ed-stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with (90)Y radioemb

248 onths with no significant difference between portal vein thrombosis (PVT) versus no PVT (7 versus 13

249 The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients

250 tients with chronic noncirrhotic, nontumoral portal vein thrombosis (PVT), the usually recommended st

251 ocellular carcinoma (HCC), including 16 with portal vein thrombosis (PVT), were treated with (90)Y-lo

252 leeding from portal hypertension but also by portal vein thrombosis (PVT).

253 yndrome (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT).

254 wo (16.3%) patients developed pre-transplant portal vein thrombosis and its presence had no impact in

255 Portal vein thrombosis at listing was not associated wit

256 Portal vein thrombosis at LT is associated with early (9

257 Budd-Chiari syndrome (BCS) and portal vein thrombosis have been reported to be associat

258 We aimed to characterize the pre-transplant portal vein thrombosis in a cohort of liver transplant r

259 Portal vein thrombosis is a frequent complication in end

260 atocellular carcinoma (HCC) with and without portal vein thrombosis underwent radioembolization with

261 Portal vein thrombosis was independently associated with

262 Portal vein thrombosis was present in 11 patients (6%).

263 60.1 years; range, 32-75 years) with HCC and portal vein thrombosis who were examined with both contr

264 Two donors developed portal vein thrombosis, and 1 had inferior vena caval th

265 as hepatorenal syndrome, hepatichydrothorax, portal vein thrombosis, and Budd-Chiari syndrome.

266 analysis Child-Pugh score, presence of HCC, portal vein thrombosis, and lack of secondary prophylaxi

267 tis/cholecystitis, pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehyd

268 patients with Budd-Chiari syndrome and with portal vein thrombosis, Kiladjian et al observed that JA

269 nt differences in hepatic artery thrombosis, portal vein thrombosis, primary nonfunction, and biliary

270 There was no incidence of hepatic artery or portal vein thrombosis.

271 Three (2.9%) grafts were lost due to portal vein thrombosis.

272 y independent risk factor for pre-transplant portal vein thrombosis.

273 es because of unexpected acute rejection and portal vein thrombosis.

274 ing for age, sex, treatment, tumor size, and portal vein thrombosis.

275 ut was present in 62.5% of the patients with portal vein thrombosis.

276 as associated with an increased incidence of portal-vein thrombosis, as compared with placebo.

277 and the hepatic artery, with the peak of the portal vein time-activity curve being delayed and disper

278 Portal vein tissue displays a severalfold decrease in pa

279 y the epithelial layer or by transit via the portal vein to the liver where they can have additional

280 e hepatic artery, gastroduodenal artery, and portal vein to the microvascular blood flow in the commo

281 ver transplantation, the contribution of the portal vein to the microvascular blood flow through the

282 to a 50-year-old man weighing 92 kg, and the portal vein to the right remnant liver was closed.

283 Portal vein tumor thrombus (PVTT) is strongly correlated

284 eport that TMED3 was up-regulated in HCC and portal vein tumor thrombus.

285 venous system and subsequently develop into portal vein tumour thrombosis (PVTT).

286 Presence of tumor thrombi in the portal veins (venous metastases) is a clinicopathologica

287 ial regression of tumor contact with the SMV/portal vein was associated in all cases with R0 resectio

288 lease of cortisol from visceral tissues into portal vein was not detected.

289 THF, only 4 +/- 18% of labeled folate in the portal vein was unmodified 5-FormylTHF, and the rest had

290 80 +/- 12% of labeled folate in the hepatic portal vein was unmodified folic acid.

291 By delivering the parasite directly into the portal vein, we demonstrated that an ongoing intestinal

292 ilarly, no afferent inputs from the liver or portal vein were found.

293 protocol (P </= .04), but CNRs for liver and portal vein were similar (P = .54 and .73, respectively)

294 ormation is a rare congenital anomaly of the portal vein where the portal blood bypasses the liver.

295 ls, termed the ductal plate, surrounding the portal vein, which eventually remodels into the branchin

296 tocytes are usually infused into the hepatic portal vein with many cells rapidly cleared by the innat

297 nificantly reduced the number of CTCs in the portal vein with no benefit in survival outcomes compare

298 aneous puncture of the left hepatic and left portal vein with subsequent guidewire snaring to perform

299 how well-developed portal triads around most portal veins, with no elevation of serum bilirubin.

300 -positive cells are detected surrounding the portal vein, yet they are unable to form biliary tubes,